Atea Pharmaceuticals, Inc. Basic Shares Outstanding (Weighted Average)
Atea Pharmaceuticals, Inc. (AVIR) reported Basic Shares Outstanding (Weighted Average) of 80.05 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 80.05M shares, a 4.41% decline year-over-year.
- Atea Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 79.20M shares, a 7.00% decline year-over-year.
- Atea Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 78.11M shares, a 7.52% decline year-over-year.
- Atea Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 79.05M shares, a 6.36% decline year-over-year.
- Atea Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 81.50M shares, a 3.29% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 84.26M shares, a 1.05% increase from fiscal 2023.
- Atea Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 83.39M shares, a 0.17% increase from fiscal 2022.
- Atea Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 83.25M shares, a 0.51% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 80.05M shares 10-Q · filed 2026-08-12 | 79.18M shares 10-Q · filed 2026-08-12 | 79.12M shares derived: average of 3 quarters · filed 2026-08-12 | 79.10M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 79.20M shares 10-Q · filed 2026-05-12 | 78.65M shares derived: average of 2 quarters · filed 2026-05-12 | 78.79M shares derived: average of 3 quarters · filed 2026-05-12 | 80.03M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 78.11M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 78.58M shares derived: average of 2 quarters · filed 2026-03-05 | 80.30M shares derived: average of 3 quarters · filed 2026-08-12 | 81.50M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 79.05M shares 10-Q · filed 2025-11-12 | 81.40M shares derived: average of 2 quarters · filed 2026-08-12 | 82.62M shares 10-Q · filed 2025-11-12 | 83.11M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 83.75M shares 10-Q · filed 2026-08-12 | 84.45M shares 10-Q · filed 2026-08-12 | 84.46M shares derived: average of 3 quarters · filed 2026-08-12 | 84.45M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 85.16M shares 10-Q · filed 2026-05-12 | 84.81M shares derived: average of 2 quarters · filed 2026-05-12 | 84.68M shares derived: average of 3 quarters · filed 2026-05-12 | 84.57M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 84.46M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 84.44M shares derived: average of 2 quarters · filed 2026-03-05 | 84.38M shares derived: average of 3 quarters · filed 2026-03-05 | 84.26M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 84.42M shares 10-Q · filed 2025-11-12 | 84.34M shares derived: average of 2 quarters · filed 2025-11-12 | 84.20M shares 10-Q · filed 2025-11-12 | 84.01M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 84.25M shares 10-Q · filed 2025-08-07 | 84.07M shares 10-Q · filed 2025-08-07 | 83.87M shares derived: average of 3 quarters · filed 2025-08-07 | 83.75M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 83.92M shares 10-Q · filed 2025-05-12 | 83.68M shares derived: average of 2 quarters · filed 2025-05-12 | 83.58M shares derived: average of 3 quarters · filed 2025-05-12 | 83.54M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 83.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 83.42M shares derived: average of 2 quarters · filed 2025-03-06 | 83.41M shares derived: average of 3 quarters · filed 2025-03-06 | 83.39M shares 10-K · filed 2025-03-06 |
| 2023-09-30 | 83.40M shares 10-Q · filed 2024-11-07 | 83.40M shares derived: average of 2 quarters · filed 2024-11-07 | 83.37M shares 10-Q · filed 2024-11-07 | 83.35M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 83.40M shares 10-Q · filed 2024-08-07 | 83.36M shares 10-Q · filed 2024-08-07 | 83.34M shares derived: average of 3 quarters · filed 2024-08-07 | 83.32M shares derived: average of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | 83.33M shares 10-Q · filed 2024-05-14 | 83.31M shares derived: average of 2 quarters · filed 2024-05-14 | 83.29M shares derived: average of 3 quarters · filed 2024-05-14 | 83.28M shares derived: average of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | 83.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 83.27M shares derived: average of 2 quarters · filed 2024-02-28 | 83.27M shares derived: average of 3 quarters · filed 2024-02-28 | 83.25M shares 10-K · filed 2024-02-28 |
| 2022-09-30 | 83.26M shares 10-Q · filed 2023-11-08 | 83.26M shares derived: average of 2 quarters · filed 2023-11-08 | 83.23M shares 10-Q · filed 2023-11-08 | 83.20M shares derived: average of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | 83.26M shares 10-Q · filed 2023-08-08 | 83.22M shares 10-Q · filed 2023-08-08 | 83.18M shares derived: average of 3 quarters · filed 2023-08-08 | 83.09M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 83.18M shares 10-Q · filed 2023-05-08 | 83.14M shares derived: average of 2 quarters · filed 2023-05-08 | 83.03M shares derived: average of 3 quarters · filed 2023-05-08 | 82.96M shares derived: average of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | 83.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 82.96M shares derived: average of 2 quarters · filed 2023-02-28 | 82.89M shares derived: average of 3 quarters · filed 2023-02-28 | 82.82M shares 10-K · filed 2023-02-28 |
| 2021-09-30 | 82.82M shares 10-Q · filed 2022-11-07 | 82.78M shares derived: average of 2 quarters · filed 2022-11-07 | 82.73M shares 10-Q · filed 2022-11-07 | 76.05M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 82.74M shares 10-Q · filed 2022-08-08 | 82.66M shares 10-Q · filed 2022-08-08 | 73.80M shares derived: average of 3 quarters · filed 2023-02-28 | 57.88M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 82.58M shares 10-Q · filed 2022-05-10 | 69.33M shares derived: average of 2 quarters · filed 2023-02-28 | 49.59M shares derived: average of 3 quarters · filed 2023-02-28 | 39.71M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | 56.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 33.09M shares derived: average of 2 quarters · filed 2023-02-28 | 25.43M shares derived: average of 3 quarters · filed 2023-02-28 | 21.59M shares 10-K · filed 2023-02-28 |
| 2020-09-30 | 10.11M shares 10-Q · filed 2021-11-12 | 10.10M shares derived: average of 2 quarters · filed 2021-11-12 | 10.10M shares 10-Q · filed 2021-11-12 | |
| 2020-06-30 | 10.10M shares 10-Q · filed 2021-08-12 | 10.09M shares 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | 10.09M shares 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | 10.09M shares 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |